Buy Cerebrolysin in Canada: A Researcher’s Guide
Cerebrolysin is not a single peptide but a defined mixture of low-molecular-weight neuropeptides and amino acids, studied for its association with neurotrophic signalling in neuroprotection and cognition research models. It is supplied as a higher-mass vial than most single peptides, and it has a larger clinical literature than almost anything else in a research catalogue. This guide covers what it is, what the trials show, and how Canadian researchers can order it.
View product →At a glance: Vistara Labs stocks Cerebrolysin in 60 mg vials, independently tested, with a certificate of analysis on our Lab Reports page, shipped from within Canada by Canada Post Xpresspost, with same-business-day dispatch on orders before 3 pm Pacific. We deliver to every province, including Ontario, Quebec, British Columbia and Alberta.
What Cerebrolysin is
Cerebrolysin is produced by the controlled enzymatic breakdown of purified pig brain proteins. The result is a mixture of short peptides and free amino acids rather than one defined sequence, which is why it behaves differently from a synthetic peptide such as Semax: its activity is attributed to the mixture as a whole, and its research interest centres on neurotrophic, growth-factor-like signalling. The clinical product, made in Austria, is a solution given by infusion or injection and has been used for decades in stroke units across Europe and Asia. It is not an approved medicine in Canada or the United States. The research vial sold here is a separate, lyophilised laboratory material.
What the research covers
Cerebrolysin has been tested in randomised, placebo-controlled trials for stroke and brain injury. In the CARS trial (Stroke, 2016), 208 stroke patients received Cerebrolysin or placebo alongside standardised rehabilitation, and the Cerebrolysin group recovered clearly more arm-and-hand function by day 90, with safety comparable to placebo. In the CAPTAIN I trial of moderate-to-severe traumatic brain injury (Neurological Sciences, 2020), patients on Cerebrolysin did significantly better on several thinking and memory measures. Results vary by condition and by outcome measure, and research continues across stroke and brain-injury settings. We read the key trials closely in Cerebrolysin: stroke and brain-injury research, and the references below link each study.
How it is supplied
Vistara Labs stocks Cerebrolysin in a 60 mg vial, supplied in a sealed vial for laboratory research handling and third-party tested with the purity figure on the product page. It is also sold in packs of ten. Because Cerebrolysin is a mixture, the mass on the label is the total material in the vial rather than a single peptide.
Handling and storage
Keep the unopened vial cold and dark. Reconstitution uses bacteriostatic water, and the arithmetic is the same as for any vial: 60 mg with 3 mL of water gives 20 mg/mL, and with 6 mL it gives 10 mg/mL. The peptide calculator works out any other volume, and the general method is in how to reconstitute peptides with bacteriostatic water. After reconstitution, label the vial with the date and concentration and refrigerate it at 2 to 8 °C, away from light.
What comes with each Cerebrolysin order
- Certificates of analysis from independent laboratories, published for each compound on the Lab Results page.
- A clear description of what is in the vial. Cerebrolysin is a peptide mixture, and the 60 mg on the label is the total material in the vial.
- Format: a sealed vial for laboratory research handling, reconstituted with bacteriostatic water.
- Research-use framing: sold for research only; see our legal overview.
Buying Cerebrolysin in Canada
Cerebrolysin is not a controlled substance in Canada and is not an approved medicine here; the research vial is sold as a laboratory material. Every order ships from within Canada, so there is no customs step. Our team answers questions about the vial, its reconstitution or an order through the contact page, and delivery is covered in ordering peptides in Canada.
Where it fits
Cerebrolysin sits within cognitive and nootropic research alongside Semax and Selank. The wider set is on the Cognitive & Nootropic Research page.
Frequently asked questions
Where can I buy Cerebrolysin in Canada?
From domestic research suppliers. Vistara Labs stocks Cerebrolysin and ships from within Canada.
Is Cerebrolysin a single peptide?
No. It is a defined mixture of low-molecular-weight neuropeptides and amino acids, produced from purified pig brain proteins.
Is Cerebrolysin an approved drug in Canada?
No. It is used clinically in a number of countries in Europe and Asia, but it is not approved in Canada or the United States. The vial sold here is a research material.
What concentration does a 60 mg vial give?
It depends on the water added: 20 mg/mL with 3 mL of bacteriostatic water, or 10 mg/mL with 6 mL.
Is Cerebrolysin legal in Canada?
It is sold for laboratory research use only. It is not sold for human use, and nothing here is medical advice.
All products discussed are for laboratory research use only and are not for human use. Nothing on this page is medical advice, and no statement about any compound is a claim of therapeutic or cosmetic benefit.
References
Cerebrolysin has substantial human neurological research, with results that vary by condition, outcome measure and study design.
- Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trialRandomised, double-blind, placebo-controlled multicentre trial; 242 patients with vascular dementia, 24 weeks.
- Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agentRandomised, double-blind, placebo-controlled trial; 192 patients with Alzheimer's disease.
- Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized studyRandomised, double-blind, placebo-controlled pilot; 32 patients with mild traumatic brain injury.
- Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled TrialsMeta-analysis of 7 randomised trials, 1,779 acute ischaemic stroke patients; no significant superiority on major functional outcomes.
Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.
